Monday, July 20

Browsing: singlearm

Research

Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience

By NewsCancerJuly 19, 20260

Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience

Research

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial

By NewsCancerJune 24, 20260

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates…

Research

HILL: the efficacy and safety of hepatic arterial infusion chemotherapy with the FOLFOX regimen combined with lenvatinib and the PD-L1 inhibitor durvalumab in unresectable hepatocellular carcinoma: a prospective, single-arm, phase 2 clinical trial

By NewsCancerMay 15, 20260

Despite rapid advances in systemic therapy, the outcome of uHCC remains unsatisfactory. The locoregional therapies continue to play a critical…

Research

Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study

By NewsCancerMay 4, 20260

In this phase II study, total neoadjuvant chemotherapy combined with a PD‑1 antibody and IL‑2 for mid–low LARC achieved a…

Research

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

By NewsCancerMay 1, 20260

Study design and patient populationThis was an open-label, nonrandomized, multicenter, first-in-human, phase I study. The main study (NCT04857138) and the…

Research

Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study

By NewsCancerApril 27, 20260

HDAC inhibitors represent a significant advancement for the treatment of NHL.11 In the United States, vorinostat, romidepsin, belinostat, and panobinostat…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Many cancer survivors have impairments that make using mobile devices and websites difficult

Clinical Scenarios: Matching Regimen to Patient Profile

Immunocompromised Patients with CSCC, Future Directions, and Closing Pearls

Browsing: singlearm

Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial

HILL: the efficacy and safety of hepatic arterial infusion chemotherapy with the FOLFOX regimen combined with lenvatinib and the PD-L1 inhibitor durvalumab in unresectable hepatocellular carcinoma: a prospective, single-arm, phase 2 clinical trial

Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study

Many cancer survivors have impairments that make using mobile devices and websites difficult

Clinical Scenarios: Matching Regimen to Patient Profile

Immunocompromised Patients with CSCC, Future Directions, and Closing Pearls

Debunking the biggest myths about sun safety – Cancer Research UK

Many cancer survivors have impairments that make using mobile devices and websites difficult

Clinical Scenarios: Matching Regimen to Patient Profile

Immunocompromised Patients with CSCC, Future Directions, and Closing Pearls

Debunking the biggest myths about sun safety – Cancer Research UK

Latest Post

Many cancer survivors have impairments that make using mobile devices and websites difficult

Clinical Scenarios: Matching Regimen to Patient Profile

Immunocompromised Patients with CSCC, Future Directions, and Closing Pearls

Subscribe to Updates

What's Hot

Browsing: singlearm